Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Centessa Pharmaceuticals Plc ADR
(NQ:
CNTA
)
8.740
+0.160 (+1.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Centessa Pharmaceuticals Plc ADR
< Previous
1
2
3
4
5
Next >
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
June 10, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
May 21, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
May 13, 2024
CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
May 13, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Where Centessa Pharmaceuticals Stands With Analysts
August 15, 2023
Via
Benzinga
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
April 23, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
April 23, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
April 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023
March 28, 2024
CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
March 28, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
February 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 09, 2024
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.
Via
Benzinga
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
February 09, 2024
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
February 09, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
January 22, 2024
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
December 13, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
December 10, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
November 27, 2023
Via
Benzinga
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
November 27, 2023
From
AnaptysBio, Inc.
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
November 13, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
November 02, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
October 31, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
October 30, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
October 26, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
October 25, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
October 03, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 31, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
August 23, 2023
Oral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disorders
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
August 14, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.